Marcus Ruscetti, PhD, and Prabhani Atukorale, PhD, have received an NCI R01 grant to advance a multi-targeted nanoparticle-based immunotherapy designed to improve treatment of pancreatic cancer.

Genome editing researcher Scot Wolfe, PhD, is collaborating with muscle biologist Charles Emerson, Jr., PhD, to develop a human muscle xenograft platform for optimizing genome editing therapies for muscular dystrophies.

Sharon Cantor, PhD, has received an R01 grant from the National Cancer Institute to explore the role of BRCA1 in coordinating lagging strand DNA synthesis, with implications for developing new treatments for hereditary breast and ovarian cancers, including tumors resistant to PARP inhibitors.

Scot Wolfe, PhD, is developing a CRISPR-Cas9 strategy to selectively destroy cancer cells driven by focal gene amplification.

Richard Gregory, PhD, is one of eight scientists in the country to receive a 2026 Lotus Award from the Pershing Square Foundation to advance innovative ovarian cancer research.

Marcus Ruscetti, PhD, has received the 2026 Pershing Square Sohn Cancer Prize in recognition of his innovative research accelerating progress toward a cure for pancreatic cancer.

Xin Yang, PhD, an Instructor in the Gregory Lab, has received an NIH R03 grant to develop a new method for mapping the 3-methylcytidine (m3C) RNA modification throughout the mRNA transcriptome in cancer.

Michael Lodato, PhD, has been awarded a one-year Research Seed Money Grant from the National Ataxia Foundation to investigate how somatic mutations in Purkinje cells contribute to neurodegeneration in Ataxia Telangiectasia.

Craig Ceol, PhD, will study whether targeting the bone morphogenetic protein signaling ligand GDF6 can provide an effective therapy for immunotherapy-resistant melanoma.

Junhao Mao, PhD, and Thomas Carroll, PhD, will study how transcription factors TAZ and SRF drive immune evasion in sarcomatoid renal cell carcinoma, with the goal of identifying new immunotherapy targets and predictive biomarkers.